Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,295 signal articles · 46 in last 24h · 115,554 total before filter · latest 2h ago
46last 24h
1762last 7d
299● bullish (7d)
168● bearish (7d)
205publishers
AllMacro314Earnings816M&A103Regulatory25Product16Analyst26
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Sezzle Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Sezzle Q2 Earnings Call Highlights

Sezzle (NASDAQ:SEZL) reported record second-quarter results for 2026, with gross merchandise volume, revenue, subscriber growth and profitability all increasing from a year earlier. The buy now, pay later company also raised its full-year revenue and adjusted earnings outlook, citing momentum across

SharonAI Holdings, Inc. Class A Common Stock Q2 Earnings Call Highlights
MarketBeat9d agoneutral
SharonAI Holdings, Inc. Class A Common Stock Q2 Earnings Call Highlights

SharonAI Holdings, Inc. Class A Common Stock (NASDAQ:SHAZ) said it expanded its secured AI factory capacity, contract backlog and funding during the second quarter, as the company works to deploy GPU infrastructure across Australia and New Zealand. Chief Executive Officer and co-founder James Manni

Serve Robotics Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Serve Robotics Q2 Earnings Call Highlights

Serve Robotics (NASDAQ:SERV) reported second-quarter revenue growth but sharply reduced its full-year outlook after delivery volume through Uber declined for the first time in 17 quarters, prompting the company to reassess the future of the partnership and redirect resources toward other channels.

Roivant Sciences Q1 Earnings Call Highlights
MarketBeat9d agoneutral
Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

B. Riley Financial Q2 Earnings Call Highlights
MarketBeat9d agoneutral
B. Riley Financial Q2 Earnings Call Highlights

B. Riley Financial (NASDAQ:RILY) reported second-quarter net income attributable to common shareholders of $19 million, or $0.45 per diluted share, as its capital markets, wealth management and communications businesses contributed to what Chairman, Founder and Co-CEO Bryant Riley called the company

Rigetti Computing Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Rigetti Computing Q2 Earnings Call Highlights

Rigetti Computing (NASDAQ:RGTI) reported second-quarter 2026 revenue of approximately $5.1 million, up from $1.8 million a year earlier, as the quantum computing company recognized revenue from previously announced on-premises Novera quantum processing unit purchase orders. Chief Executive Officer

REGENXBIO Q2 Earnings Call Highlights
MarketBeat9d agoneutral
REGENXBIO Q2 Earnings Call Highlights

REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic

Red Cat Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Red Cat Q2 Earnings Call Highlights

Red Cat (NASDAQ:RCAT) reported second-quarter 2026 revenue of $20.2 million, up 520% from $3.2 million a year earlier, as deliveries across its drone portfolio and defense programs increased. The company said revenue for the first six months of 2026 reached $35.7 million, compared with $4.8 million

PubMatic Q2 Earnings Call Highlights
MarketBeat9d agoneutral
PubMatic Q2 Earnings Call Highlights

PubMatic (NASDAQ:PUBM) reported second-quarter revenue growth of 11% year over year, returning to double-digit growth ahead of its prior expectations, as the company cited momentum in connected TV, mobile applications and AI-powered products. Adjusted EBITDA rose 38% from a year earlier to $19.6 mi

Paramount Skydance Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Paramount Skydance Q2 Earnings Call Highlights

Paramount Skydance (NASDAQ:PSKY) said its second-quarter performance reflected progress in its efforts to expand streaming, rebuild its studios business and reduce costs, while management reaffirmed confidence in the company’s proposed combination with Warner Bros. Discovery. Chairman and Chief Exe

PENN Entertainment Q2 Earnings Call Highlights
MarketBeat9d agoneutral
PENN Entertainment Q2 Earnings Call Highlights

PENN Entertainment (NASDAQ:PENN) reported record second-quarter retail revenue and raised its full-year outlook for the segment, while management said its interactive business continued to narrow losses through lower marketing spending, cost efficiencies and growth in online casino operations. Chie

Palladyne AI Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Palladyne AI Q2 Earnings Call Highlights

Palladyne AI (NASDAQ:PDYN) reported second-quarter revenue of $5.8 million, a company record that rose 63% sequentially and 470% from a year earlier, as it cited growth across its precision manufacturing, avionics, engineering services and AI development activities. The company reaffirmed its 2026

Ouster Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Ouster Q2 Earnings Call Highlights

Ouster (NASDAQ:OUST) reported second-quarter revenue of $55 million, up approximately 56% from a year earlier, as demand from industrial and smart-infrastructure customers helped the lidar and perception technology company ship a record number of sensors. Chief Executive Officer Angus Pacala said t

Ocugen Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Ocugen Q2 Earnings Call Highlights

Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa